Results 41 to 50 of about 61,558 (234)

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2

Neoplasia: An International Journal for Oncology Research, 2018
The anticancer drug temozolomide is the only drug with proven activity against high-grade gliomas and has therefore become a part of the standard treatment of these tumors.
Mark C. de Gooijer, Nienke A. de Vries, Tessa Buckle, Levi C.M. Buil, Jos H. Beijnen, Willem Boogerd, Olaf van Tellingen   +6 more
doaj   +1 more source

3D Bioprinted Glioblastoma Multiforme Models: How the Extracellular Matrix Glycosignature Influences Drug Response

Advanced Functional Materials, EarlyView.
Aberrant glycosylation in the glioblastoma tumor microenvironment drives therapeutic resistance. Here, a 3D bioprinted model was engineered by incorporating α‐NeuNAc‐(2→3)‐β‐D‐Gal‐ and chondroitin sulfate. Combined multiplex immunofluorescence and synchrotron‐based nanoCT analysis revealed that glycan‐matrix interactions dictate specific drug‐escape ...
Francesca Cadamuro, Marco Piazzoni, Ilaria Borghi, Alberto Baeri, Alessandro Fumagalli, Federica Perillo, Hafiz Muhammad Fahad, Martina Ghizzi, Luca Crippa, Gabriella Nicolini, Angela Bentivegna, Daniele Ramazzotti, Valentina Zuliani, Mirko Rivara, Carlo Giorgio Giussani, Andrea Di Cristofori, Guido Cavaletti, Federica Facciotti, Sobhan Sheikhi, Claire Seydoux, Murielle Salome, Peter Cloetens, Alberto Bravin, Paola Coan, Francesco Nicotra, Laura Russo   +25 more
wiley   +1 more source

Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity

Cellular Physiology and Biochemistry, 2018
Background/Aims: Cyclin D1 (CCND1) is frequently overexpressed in malignant gliomas. We have previously shown ectopic overexpression of CCND1 in human malignant gliomas cell lines.
Danfeng Zhang, Dawei Dai, Mengxia Zhou, Zhenxing Li, Chunhui Wang, Yicheng Lu, Yiming Li, Junyu Wang   +7 more
doaj   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

The Synergistic Effects of the Combination of Ciprofloxacin and Temozolomide on Human Glioblastoma A-172 Cell Line

Middle East Journal of Cancer, 2017
Background: Combination therapy has generated remarkable motivation in the clinical setting since it boosts the therapeutic potential of anticancer drugs.
Ashkan Zandi, Taraneh Moini Zanjani, Seyed Ali Ziai, Yalda Khazaei Poul, Mostafa Haji Molla Hoseini   +4 more
doaj  

Current chemotherapy strategies for adults with IDH-wildtype glioblastoma

Frontiers in Oncology
IntroductionGlioblastoma, despite advancements in molecular evolution, remains incurable and has low survival rates. Currently, two of the most commonly used chemotherapy regimens are temozolomide and CCNU.
Jing Bao, Rui Sun, Zhenjiang Pan, Shepeng Wei   +3 more
doaj   +1 more source

Rapid In Vitro Pathological Diagnosis of Glioma Using Dual‐Color Quantum Dot Probes for Precise Intraoperative Resection

Advanced Science, EarlyView.
Glioma resection surgery is challenging because of the infiltrative growth of the tumor into nearby tissue and the different surgical requirements for gliomas with different mutation types. To improve the precision and effectiveness of glioma resection, this study developed a new imaging probe that enables the tumor boundary and mutation status to be ...
Dongdong Wu, Chenxuan Yang, Yuanbin Wu, Minghang Liu, Yizhi Zhang, Yuang Cai, Yibo Zhang, Jimei Chi, Hengchao Ma, Ding Zhang, Chenqing Liu, Meng Su, Guochen Sun   +12 more
wiley   +1 more source

Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data

Drug Design, Development and Therapy, 2021
Chen Shi,1,2 Xiong Wang,1,2 Changdong Diao,1,2 Haixia Zhu,1,2 Qi Yuan,1,2 Jinmei Liu,1,2 Shijun Li,1,2 Ming Gu,1,2 Yu Zhang1,2 1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan,
Shi C, Wang X, Diao C, Zhu H, Yuan Q, Liu J, Li S, Gu M, Zhang Y   +8 more
doaj  

LRRC4 Orchestrates AP2A1‐Containing Clathrin‐Coated Vesicles to Disrupt Mitochondrial Cristae and Restrict Glioblastoma Progression

Advanced Science, EarlyView.
LRRC4 suppresses GBM by regulating AP2A1‐containing Golgi‐derived clathrin‐coated vesicles. Low LRRC4 allows cytoplasmic AP2A1 to maintain mitochondrial fission‐fusion, MICOS integrity, and OXPHOS, promoting proliferation and invasion. High LRRC4 redirects AP2A1‐containing Golgi‐derived clathrin‐coated vesicles to mitochondria, disrupts MICOS, enhances
Yang Li, Cheng Huang, Liangqi Jiang, Zhen Li, Qing Liu, Minghua Wu   +5 more
wiley   +1 more source

TET1 Inhibition Promotes Therapeutic Sensitivity in TP53‐Mutant GBM by Influencing Genome Fragility and Altering TAMs Biology

Advanced Science, EarlyView.
In TP53mut GBM cells, reduced P53 function is associated with increased TET1 expression. Genetic or pharmacological inhibition of TET1 correlates with genome fragility, including DNA damage, cellular senescence, telomere shortening, and reactive oxygen species accumulation, which may contribute to increased efficacy of antitumor therapy.
Zhuonan Pu, Jinqiu Liu, Yuxuan Deng, Shuyu Hao, Xiaoli Zhang, Mingxu Yang, Chao Guo, Chao Du, Yingdan Chen, Tai Sun, Nan Ji, Zhengping Zhuang, Jie Feng   +12 more
wiley   +1 more source